Aβ and Tau Structure-based Biomarkers for a Blood- and CSF-based Two-step Recruitment Strategy to Identify Patients with Dementia Due to Alzheimer's Disease

Overview

Journal Alzheimers Dement (Amst)

Date 2019 Mar 27

PMID 30911600

Citations 17

Authors

Andreas Nabers

Henning Hafermann

Jens Wiltfang

Klaus Gerwert

Affiliations

Soon will be listed here.

Abstract

Introduction: Alzheimer's disease (AD) diagnosis requires invasive CSF analysis or expensive brain imaging. Therefore, a minimal-invasive reliable and cost-effective blood test is requested to power large clinical AD trials at reduced screening failure.

Methods: We applied an immuno-infrared sensor to measure the amyloid-β (Aβ) and tau secondary structure distribution in plasma and CSF as structure-based biomarkers for AD (61 disease controls, 39 AD cases).

Results: Within a first diagnostic screening step, the structure-based Aβ blood biomarker supports AD identification with a sensitivity of 90%. In a second diagnostic validation step, the combined use of the structure-based CSF biomarkers Aβ and tau excluded false-positive cases which offers an overall specificity of 97%.

Discussion: The primary Aβ-based blood biomarker funnels individuals with suspected AD for subsequent validation of the diagnosis by structure-based combined analysis of the CSF biomarkers Aβ and tau. Our novel two-step recruitment strategy substantiates the diagnosis of AD with a likelihood of 29.

Citing Articles

Bee Pollen as a Source of Biopharmaceuticals for Neurodegeneration and Cancer Research: A Scoping Review and Translational Prospects.

Kacemi R, Campos M Molecules. 2025; 29(24).

PMID: 39769981 PMC: 11677910. DOI: 10.3390/molecules29245893.

Probing Chemical Complexity of Amyloid Plaques in Alzheimer's Disease Mice using Hyperspectral Raman Imaging.

Mrdenovic D, Combes B, Ni R, Zenobi R, Kumar N ACS Chem Neurosci. 2023; 15(1):78-85.

PMID: 38096362 PMC: 10767745. DOI: 10.1021/acschemneuro.3c00607.

Artificial intelligence-coupled plasmonic infrared sensor for detection of structural protein biomarkers in neurodegenerative diseases.

Kavungal D, Magalhaes P, Kumar S, Kolla R, Lashuel H, Altug H Sci Adv. 2023; 9(28):eadg9644.

PMID: 37436975 PMC: 10337894. DOI: 10.1126/sciadv.adg9644.

SOBA: Development and testing of a soluble oligomer binding assay for detection of amyloidogenic toxic oligomers.

Shea D, Colasurdo E, Smith A, Paschall C, Jayadev S, Keene C Proc Natl Acad Sci U S A. 2022; 119(50):e2213157119.

PMID: 36490316 PMC: 9897489. DOI: 10.1073/pnas.2213157119.

Unfolded p53 in non-neuronal cells supports bacterial etiology of Alzheimer's disease.

French P Neural Regen Res. 2022; 17(12):2619-2622.

PMID: 35662191 PMC: 9165400. DOI: 10.4103/1673-5374.339476.

References

Mapstone M, Cheema A, Fiandaca M, Zhong X, Mhyre T, MacArthur L . Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med. 2014; 20(4):415-8. PMC: 5360460. DOI: 10.1038/nm.3466. View

Nabers A, Perna L, Lange J, Mons U, Schartner J, Guldenhaupt J . Amyloid blood biomarker detects Alzheimer's disease. EMBO Mol Med. 2018; 10(5). PMC: 5938617. DOI: 10.15252/emmm.201708763. View

Olsson B, Lautner R, Andreasson U, Ohrfelt A, Portelius E, Bjerke M . CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol. 2016; 15(7):673-684. DOI: 10.1016/S1474-4422(16)00070-3. View

Noel-Storr A, McCleery J, Richard E, Ritchie C, Flicker L, Cullum S . Reporting standards for studies of diagnostic test accuracy in dementia: The STARDdem Initiative. Neurology. 2014; 83(4):364-73. PMC: 4115600. DOI: 10.1212/WNL.0000000000000621. View

Simonsen A, Herukka S, Andreasen N, Baldeiras I, Bjerke M, Blennow K . Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimers Dement. 2017; 13(3):274-284. DOI: 10.1016/j.jalz.2016.09.008. View

Zhao X, Lejnine S, Spond J, Zhang C, Ramaraj T, Holder D . A candidate plasma protein classifier to identify Alzheimer's disease. J Alzheimers Dis. 2014; 43(2):549-63. DOI: 10.3233/JAD-141149. View

Lewczuk P, Zimmermann R, Wiltfang J, Kornhuber J . Neurochemical dementia diagnostics: a simple algorithm for interpretation of the CSF biomarkers. J Neural Transm (Vienna). 2009; 116(9):1163-7. DOI: 10.1007/s00702-009-0277-y. View

Nabers A, Ollesch J, Schartner J, Kotting C, Genius J, Hafermann H . Amyloid-β-Secondary Structure Distribution in Cerebrospinal Fluid and Blood Measured by an Immuno-Infrared-Sensor: A Biomarker Candidate for Alzheimer's Disease. Anal Chem. 2016; 88(5):2755-62. DOI: 10.1021/acs.analchem.5b04286. View

Nabers A, Ollesch J, Schartner J, Kotting C, Genius J, Haussmann U . An infrared sensor analysing label-free the secondary structure of the Abeta peptide in presence of complex fluids. J Biophotonics. 2015; 9(3):224-34. DOI: 10.1002/jbio.201400145. View

10.

Hendrix J, Finger B, Weiner M, Frisoni G, Iwatsubo T, Rowe C . The Worldwide Alzheimer's Disease Neuroimaging Initiative: An update. Alzheimers Dement. 2015; 11(7):850-9. DOI: 10.1016/j.jalz.2015.05.008. View

11.

Nakamura A, Kaneko N, Villemagne V, Kato T, Doecke J, Dore V . High performance plasma amyloid-β biomarkers for Alzheimer's disease. Nature. 2018; 554(7691):249-254. DOI: 10.1038/nature25456. View

12.

Snyder H, Carrillo M, Grodstein F, Henriksen K, Jeromin A, Lovestone S . Developing novel blood-based biomarkers for Alzheimer's disease. Alzheimers Dement. 2013; 10(1):109-14. PMC: 4769619. DOI: 10.1016/j.jalz.2013.10.007. View

13.

Jack Jr C, Therneau T, Wiste H, Weigand S, Knopman D, Lowe V . Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study. Lancet Neurol. 2015; 15(1):56-64. PMC: 4784263. DOI: 10.1016/S1474-4422(15)00323-3. View

14.

Verberk I, Slot R, Verfaillie S, Heijst H, Prins N, van Berckel B . Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes. Ann Neurol. 2018; 84(5):648-658. PMC: 6282982. DOI: 10.1002/ana.25334. View

15.

Ovod V, Ramsey K, Mawuenyega K, Bollinger J, Hicks T, Schneider T . Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement. 2017; 13(8):841-849. PMC: 5567785. DOI: 10.1016/j.jalz.2017.06.2266. View

16.

McKhann G, Knopman D, Chertkow H, Hyman B, Jack Jr C, Kawas C . The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7(3):263-9. PMC: 3312024. DOI: 10.1016/j.jalz.2011.03.005. View

17.

Fandos N, Perez-Grijalba V, Pesini P, Olmos S, Bossa M, Villemagne V . Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals. Alzheimers Dement (Amst). 2017; 8:179-187. PMC: 5602863. DOI: 10.1016/j.dadm.2017.07.004. View

18.

Wang Y, Mandelkow E . Tau in physiology and pathology. Nat Rev Neurosci. 2015; 17(1):5-21. DOI: 10.1038/nrn.2015.1. View

19.

Paraskevaidi M, Martin-Hirsch P, Martin F . Progress and Challenges in the Diagnosis of Dementia: A Critical Review. ACS Chem Neurosci. 2018; 9(3):446-461. DOI: 10.1021/acschemneuro.8b00007. View

20.

Dubois B, Feldman H, Jacova C, Hampel H, Molinuevo J, Blennow K . Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 2014; 13(6):614-29. DOI: 10.1016/S1474-4422(14)70090-0. View